Two doses of Covaxin, India's indigenous COVID-19 vaccine, offer 77.8 per cent protection against symptomatic disease and present no serious safety concerns, according to an interim analysis of its......
The first COVID-19 vaccine to reach phase I clinical trial is safe, well-tolerated, and capable of generating an immune response against the novel coronavirus in humans, says a new research......